Somewhat Favorable Media Coverage Somewhat Unlikely to Impact PTC Therapeutics (NASDAQ:PTCT) Stock Price

Headlines about PTC Therapeutics (NASDAQ:PTCT) have trended somewhat positive this week, Accern reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. PTC Therapeutics earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.398354880133 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

These are some of the media headlines that may have effected Accern’s rankings:

PTC Therapeutics (NASDAQ PTCT) opened at $21.71 on Friday. The stock has a market capitalization of $880.82, a P/E ratio of -7.51 and a beta of 1.23. PTC Therapeutics has a 12-month low of $8.12 and a 12-month high of $22.00. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.08 and a quick ratio of 2.97.

A number of research analysts have weighed in on the company. ValuEngine upgraded PTC Therapeutics from a “strong sell” rating to a “sell” rating in a report on Tuesday. JPMorgan Chase & Co. cut PTC Therapeutics from a “neutral” rating to an “underweight” rating and dropped their price target for the stock from $23.00 to $15.00 in a research report on Monday, October 9th. Citigroup reissued a “buy” rating and issued a $28.00 price target on shares of PTC Therapeutics in a research report on Wednesday, September 27th. Credit Suisse Group reissued an “outperform” rating and issued a $25.00 price target on shares of PTC Therapeutics in a research report on Tuesday, September 26th. Finally, Zacks Investment Research raised PTC Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, October 31st. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the company. PTC Therapeutics currently has an average rating of “Hold” and a consensus target price of $19.14.

In other PTC Therapeutics news, CEO Stuart Walter Peltz sold 2,230 shares of the business’s stock in a transaction on Friday, January 5th. The shares were sold at an average price of $18.03, for a total transaction of $40,206.90. Following the completion of the sale, the chief executive officer now directly owns 26,646 shares in the company, valued at approximately $480,427.38. The sale was disclosed in a document filed with the SEC, which is available through this link. Insiders sold a total of 2,719 shares of company stock worth $48,848 over the last ninety days. 8.10% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact PTC Therapeutics (NASDAQ:PTCT) Stock Price” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.

Insider Buying and Selling by Quarter for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply